Core Insights - The company ended 2025 with strong execution, achieving revenue growth in both interventional glaucoma and interventional dry eye segments, and aims for double-digit growth in 2026 while maintaining operational discipline [1][16] - The interventional technologies, OMNI and TearCare, target prevalent diseases such as glaucoma and dry eye, presenting significant long-term market opportunities [1][5] Financial Performance - Total revenue for Q4 2025 was $20.4 million, a 7% increase year-over-year, with interventional glaucoma revenue at $19.7 million (up 5%) and interventional dry eye revenue at $700,000 (up from $300,000) [17][18] - Gross margins were strong, with interventional glaucoma at 88% and interventional dry eye improving to 68% [18] - Operating expenses decreased by 25% to $21.5 million, reflecting cost management efforts, including a reduction in force [18][19] Market Strategy - The company is focusing on interventional glaucoma and interventional dry eye, with a strategy to enhance customer engagement and expand market access [6][12] - The interventional dry eye segment is expected to grow significantly, with a revenue guidance of $5 million to $7 million for 2026, compared to $1.6 million in the prior year [20] - The company aims to pioneer the reimbursed interventional dry eye market, having established pricing for the TearCare procedure with two MACs [8][12] Growth Drivers - The interventional glaucoma market is expected to grow in the low- to mid-single digits, with a focus on expanding the combo cataract segment and standalone market opportunities [20][26] - The company is investing in commercial infrastructure to support growth in both interventional segments, particularly in areas with established reimbursement [12][41] - The potential for TearCare is significant, with an estimated 700,000 patients in the targeted MAC regions suffering from moderate to severe dry eye disease [44][50] Future Outlook - Revenue guidance for 2026 is set at $82 million to $88 million, reflecting a growth of 6% to 14% compared to 2025 [20][22] - The company anticipates that the first quarter of 2026 will be the lowest for interventional glaucoma, with expectations for growth in the second half of the year [21][56] - Continued engagement with additional MACs and commercial payers is critical for expanding access and accelerating adoption of interventional dry eye treatments [12][61]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, while interventional dry eye revenue was $0.7 million, up from $0.3 million [17][19] - Gross margin was 87%, consistent with the prior year, with interventional glaucoma gross margin at 88% and interventional dry eye gross margin improved to 68% from 51% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] Business Line Data and Key Metrics Changes - Interventional dry eye revenue in Q4 was driven by the sale of approximately 700 Smart Lids to about 80 accounts, with 30 being new engagements [9][10] - Interventional glaucoma revenue growth was supported by a 2% increase in ordering accounts and higher average selling prices [14] - The company is focused on expanding the interventional dry eye market through investments in commercial infrastructure and provider engagement [11][12] Market Data and Key Metrics Changes - The interventional glaucoma market is expected to grow in the low to mid-single digits, while the interventional dry eye segment is projected to reach $5 million-$7 million in revenue for 2026 [20][26] - The company estimates that the current MIGS market is approximately 90% combo cataract and 10% standalone, with expectations for a shift towards standalone procedures [37] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A focus on interventional solutions is expected to create multiple durable growth drivers across glaucoma and dry eye categories [7] - The company is investing in targeted commercial resources to drive education and activation in the standalone glaucoma market [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven without raising additional equity capital, supported by a strong balance sheet [17] - The company is optimistic about the growth potential in both interventional glaucoma and interventional dry eye markets, with a focus on disciplined execution [22] - Management highlighted the importance of expanding market access and engaging with additional MACs and commercial payers throughout 2026 [12][22] Other Important Information - The company has established pricing for CPT code 0563T associated with the TearCare procedure, marking a significant milestone for the interventional dry eye business model [9] - The company ended Q4 with $92 million in cash and cash equivalents, down from $120.4 million at the end of 2024 [19] Q&A Session Summary Question: Guidance assumptions for interventional glaucoma and interventional dry eye - Management indicated a stable market for interventional glaucoma and expressed excitement about growth in both segments for 2026 [25][26] Question: Underlying market growth assumptions for interventional glaucoma - Management estimates low to mid-single digit market growth for interventional glaucoma [27] Question: Standalone glaucoma market evolution and obstacles - Management discussed the need for education and activation to convert understanding of interventions into actual cases, with a focus on procedural workflows [34][36] Question: Operating expenses and investment balance - Management emphasized a focus on commercial infrastructure investments while maintaining financial discipline [44][46] Question: Revenue opportunity in MACs for dry eye - Management highlighted a significant market opportunity in MACs with 10.4 million covered lives and a high prevalence of dry eye disease [47][49] Question: Peak sales potential for TearCare - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time [55][56] Question: Impact of new goniotomy codes on reimbursement - Management discussed potential changes in reimbursement for goniotomy and its implications for OMNI technology [69][70]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, driven by increases in ordering accounts and average selling prices [17] - Interventional dry eye revenue was $0.7 million, up from $0.3 million, reflecting positive traction in the reimbursed interventional dry eye business model [17] - Gross margin was 87%, consistent with the prior year, while interventional glaucoma gross margin improved to 88% from 87% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] Business Line Data and Key Metrics Changes - Interventional dry eye segment achieved a significant reimbursement milestone with established pricing for CPT code 0563T, associated with the TearCare procedure [9] - Revenue from interventional dry eye in Q4 was driven by the sale of approximately 700 SmartLids to about 80 accounts, with around 30 being new engagements [9][10] - Interventional glaucoma revenue growth was supported by a 2% increase in ordering accounts year-over-year, with utilization remaining healthy [14] Market Data and Key Metrics Changes - The interventional glaucoma market is expected to grow in the low to mid-single digits, while the interventional dry eye market is anticipated to grow significantly due to new reimbursement opportunities [25][26] - The current MIGS market is estimated to be 90% combo cataract and 10% standalone, with expectations for a shift towards standalone procedures [36] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A focus on interventional solutions is expected to create multiple durable growth drivers across glaucoma and dry eye treatments [7] - Investments in commercial infrastructure and market access are planned to support growth in both interventional dry eye and interventional glaucoma segments [22][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven without raising additional equity capital, emphasizing operational discipline [17] - The company is optimistic about the growth potential in both segments, particularly with the recent reimbursement milestones for interventional dry eye [22] - Management highlighted the importance of educating eye care providers on the benefits of earlier intervention with minimally invasive solutions for glaucoma [33] Other Important Information - The company ended Q4 2025 with $92 million in cash and cash equivalents, down from $120.4 million at the end of 2024 [19] - The company initiated revenue guidance for 2026 of $82 million to $88 million, reflecting growth of 6% to 14% compared to 2025 [20] Q&A Session Summary Question: Guidance assumptions for interventional glaucoma and interventional dry eye - Management indicated a stable market for interventional glaucoma and emphasized prudent guidance for interventional dry eye, which is still early in its reimbursement journey [25][26] Question: Standalone glaucoma market evolution and obstacles - Management noted that activating the standalone market requires education and a structured workflow similar to cataract surgery, with ongoing investments to facilitate this transition [33][36] Question: Operating expenses and investment balance - Management confirmed that investments in commercial infrastructure will focus on both interventional dry eye and glaucoma, while maintaining financial discipline [42][44] Question: TearCare peak sales potential - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time, emphasizing the need for market access [52][54] Question: First quarter outlook for interventional glaucoma - Management cited weather-related disruptions as a factor impacting the first quarter outlook, but did not foresee other significant headwinds [59]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, while interventional dry eye revenue was $0.7 million, up from $0.3 million [17] - Gross margin was 87%, consistent with the prior year, with interventional glaucoma gross margin at 88% and interventional dry eye gross margin improved to 68% from 51% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] - Cash and cash equivalents at the end of the quarter were $92 million, down from $120.4 million at the end of 2024 [19] Business Line Data and Key Metrics Changes - Interventional dry eye revenue in Q4 was $0.7 million, driven by the sale of approximately 700 Smart Lids to about 80 accounts, with 30 being new engagements [9][10] - Interventional glaucoma revenue was $19.7 million, with ordering accounts increasing by 2% year-over-year [13] - Utilization in interventional glaucoma remained healthy, down slightly after a strong Q3 [13] Market Data and Key Metrics Changes - The interventional dry eye market is expected to grow significantly, with a focus on expanding market access and engaging new eye care providers [11][12] - The interventional glaucoma market is projected to grow in the low to mid-single digits, with a focus on expanding the combo cataract segment and standalone market opportunities [25][27] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A shift in terminology from surgical glaucoma and dry eye to interventional glaucoma and interventional dry eye reflects a focus on earlier procedure-based interventions [6] - Investments are being made in commercial infrastructure to support growth in both interventional dry eye and interventional glaucoma segments [21][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term opportunity within the interventional markets for glaucoma and dry eye, emphasizing the importance of their proprietary technologies [5][6] - The company is focused on pioneering the reimbursed interventional dry eye treatment market and enhancing customer engagement [11][12] - Management expects revenue guidance for 2026 to be between $82 million and $88 million, reflecting growth of 6% to 14% compared to 2025 [19][20] Other Important Information - The company has established pricing for CPT code 0563T associated with the TearCare procedure, marking a significant milestone for the interventional dry eye business model [9] - The company is actively engaging with additional MACs and commercial payers to accelerate adoption and expand access for patients [12][63] Q&A Session Summary Question: Can you provide color on low-end versus high-end assumptions for guidance? - Management indicated a stable market for interventional glaucoma and emphasized prudent guidance for interventional dry eye, which is still early in its market access journey [25][26] Question: What are the assumptions for underlying market growth in interventional glaucoma? - Management estimates low to mid-single digit market growth for interventional glaucoma [27] Question: How do you see the standalone glaucoma market evolving? - Management highlighted the importance of educating eye care providers on earlier interventions and activating the standalone market through targeted investments [34][36] Question: What is the revenue opportunity for dry eye in the two MACs? - Management noted a significant opportunity with 10.4 million covered lives and approximately 700,000 patients with moderate to severe MGD in those markets [46] Question: Can you discuss the peak sales potential of TearCare? - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time [51][54] Question: What is the expectation for reimbursement with new goniotomy codes? - Management is aware of the potential impact of new goniotomy codes and expects some pressure on utilization but believes it could also create a tailwind for their OMNI technology [66]

Investor Presentation March 2026 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. The Company intends such forward- looking statements to be covered by the safe harbor pro ...

Summary of Sight Sciences Conference Call Company Overview - **Company**: Sight Sciences (NasdaqGS: SGHT) - **Industry**: Eye Care, specifically focusing on treatments for meibomian gland disease (MGD) and surgical glaucoma Key Highlights from the Third Quarter - **TearCare Market Access Wins**: Successful market access for TearCare, a treatment for evaporative dry eye disease, after a decade of efforts [2][3] - **Surgical Glaucoma Performance**: Strong performance in the surgical glaucoma business, particularly in Minimally Invasive Glaucoma Surgery (MIGS) despite industry headwinds [2][3] - **Restructuring and Leadership Changes**: Streamlined operations and promoted key personnel to enhance focus on growth opportunities [3] TearCare Product Insights - **Clinical Outcomes**: TearCare demonstrated superior clinical outcomes in a randomized controlled trial (RCT) compared to standard prescription eye drops, showing durability of treatment effects over two years [6][7] - **Economic Value Proposition**: TearCare is not only clinically effective but also cost-effective, making it an attractive option for payers [7][8] - **Stakeholder Benefits**: All stakeholders benefit from reimbursed TearCare, including patients, doctors, and payers, creating a sustainable business model with high-margin recurring revenue [8][9] Market Strategy and Growth Potential - **Established Customer Base**: Over 70,000 cash pay procedures performed, indicating high demand for TearCare [14] - **Payer Density Strategy**: Focus on increasing payer density in key markets (Texas and Florida) to enhance reimbursement opportunities [15][16] - **Sales Projections**: Anticipated modest sales of $500,000 to $1,000,000 in the fourth quarter, with significant ramp-up expected in 2026 [18] Long-Term Market Potential - **Addressable Market Size**: Approximately 19 million people suffer from dry eye disease, with 6 to 8 million having moderate to severe MGD, indicating a large market opportunity [33][34] - **Recurring Treatment Model**: Patients are expected to return for treatments every six to twelve months, enhancing the total addressable market (TAM) [34][35] MIGS and Surgical Glaucoma Insights - **Market Share Gains**: Sight Sciences has gained market share in the MIGS segment, attributed to strong execution and the comprehensive nature of the Omni device [39][40] - **Growth in Combo Cataract Market**: The company aims to expand its presence in the combo cataract MIGS market, which is currently less than 50% penetrated [45] Financial Health and Guidance - **Balance Sheet Strength**: Over $90 million in cash, with a pathway to break-even without additional equity capital [52] - **Operational Expenditure**: Adjusted operational expenditure of $20 million in Q3, with guidance for Q4 suggesting a similar range for 2026 [53] Conclusion - **Future Outlook**: The company is positioned for growth in both the TearCare and surgical glaucoma segments, with a focus on executing its market strategies effectively and maintaining financial discipline as it scales operations [54][53]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $19.9 million, a 1% decrease compared to the same period in the prior year [22] - Surgical glaucoma revenue was $19.7 million, an increase of 6% year-over-year and up 3% sequentially [22][24] - Dry eye revenue decreased to $0.2 million from $1.5 million, aligning with expectations due to a focus on reimbursed market access for TearCare [22][24] - Gross margin improved to 86%, up from 84% [23] - Net loss was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share in the prior year [24] Business Line Data and Key Metrics Changes - Surgical glaucoma segment showed strong performance with increased ordering accounts and average selling prices, despite lower account utilization [22][24] - Dry eye segment is transitioning towards a focus on TearCare, with significant advancements in reimbursement coverage [9][10] - The company anticipates a revenue contribution from the dry eye segment of $500,000 to $1 million for Q4 2025 [25] Market Data and Key Metrics Changes - The establishment of fee schedules for TearCare by Novitas and First Coast is expected to cover approximately 10.4 million Medicare-covered lives [9][10] - The company estimates around 6,500 eye care providers as potential adopters of TearCare procedures [10][11] Company Strategy and Development Direction - The company is focused on expanding its market presence in both surgical glaucoma and dry eye segments, particularly through the commercialization of TearCare [21][26] - Strategic priorities include securing additional reimbursement coverage for TearCare and accelerating commercial momentum in both segments [20][21] - The management team has undergone restructuring to enhance operational efficiency and drive growth [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustained long-term growth driven by recent advancements in reimbursement for TearCare and strong performance in surgical glaucoma [8][21] - The company is optimistic about returning to growth in both business segments in 2026 [21][40] Other Important Information - The company has reduced its adjusted operating expense guidance for the full year 2025 to $90-$92 million, reflecting a decrease of 9%-11% compared to 2024 [26] - The company ended the quarter with $92.4 million in cash and cash equivalents and $40 million in debt [24] Q&A Session Summary Question: What will be the primary focus for the new COO in the next 6 to 12 months? - The COO will focus on accelerating growth and scaling the TearCare franchise, leveraging the newly established reimbursement rates [30] Question: How does the company view the opportunity from competitors repositioning their products? - The company believes it can capture growth as the MIGS market returns to growth in 2026, focusing on the benefits of its Omni product [32] Question: What initiatives are in place to build engagement and utilization for TearCare? - The company is focused on education, identification, and activation of accounts, with strong engagement from both existing and new customers [35] Question: How should investors think about the contribution of TearCare next year? - The growth rate for TearCare is expected to be significantly larger than that of the surgical glaucoma business due to its small revenue base and recurring revenue model [40] Question: What is the strategy for expanding coverage with other payers? - The company is actively engaging with other MACs and commercial payers, with a focus on Medicare Advantage plans in the same states as the established fee schedules [44]

Summary of Sight Sciences FY Conference Call (September 10, 2025) Company Overview - **Company**: Sight Sciences (NasdaqGS:SGHT) - **Industry**: Interventional Glaucoma and Dry Eye Treatment Key Points on the MIGS Market - **Market Growth**: The MIGS (Minimally Invasive Glaucoma Surgery) market is expected to return to growth in 2026 after facing headwinds due to LCD (Local Coverage Determinations) and payment changes in 2025 [3][4] - **Clinical Need**: Glaucoma is the leading cause of irreversible blindness globally, necessitating more interventional options for patients [3][5] - **Patient Visits**: There is a continuous increase in patient visits, indicating a growing demand for glaucoma treatments [3][4] - **Commercial Strategy**: The company aims to position itself strongly to capture growth when the MIGS market rebounds, emphasizing the importance of innovation and effective commercial execution [4][10] Insights on Glaucoma Treatment - **Interventional Approaches**: The future of glaucoma treatment is expected to be more interventional, with a focus on sustained release interventions and early use of SLT (Selective Laser Trabeculoplasty) [7][9] - **Patient Compliance**: The company recognizes the challenges of patient compliance with traditional treatments like eye drops, advocating for more effective interventional methods [6][9] Performance Metrics - **Q2 Performance**: Surgical glaucoma revenue was down mid-single digits, significantly better than the anticipated 15% decline due to MIGS restrictions. The company reported a 12% sequential increase in utilization [10][11] - **Surgeon Engagement**: The company has seen record numbers of ordering accounts, indicating strong engagement with its commercial team [10][11] Regulatory and Payer Dynamics - **Payer Scrutiny**: The rapid growth of the MIGS segment has led to increased scrutiny from payers, necessitating robust clinical evidence to support reimbursement [14][15] - **Clinical Evidence**: The company is focused on generating compelling clinical evidence to demonstrate the efficacy of its products, particularly the OMNI platform [16][50] OMNI Platform Innovations - **OMNI Edge**: The latest iteration of the OMNI platform, which enhances the volume of viscoelastic delivered during procedures, has received positive feedback from surgeons [17][18] - **Competitive Landscape**: The company believes it is ahead of competitors in technology and usability, which are critical factors for success in the market [20][21] Dry Eye Treatment Insights - **TearCare Development**: The company has developed TearCare to address the root causes of dry eye disease, focusing on meibomian gland dysfunction rather than tear insufficiency [25][28] - **Clinical Trials**: TearCare has completed two randomized controlled trials (RCTs) demonstrating its superiority over standard care, which is crucial for gaining reimbursement [29][50] - **Market Potential**: There are over 19 million diagnosed and an additional 19 million undiagnosed patients with dry eye disease in the U.S., indicating a significant market opportunity [43] Reimbursement Strategy - **Payer Engagement**: The company is actively engaging with payers to secure reimbursement for TearCare, leveraging strong clinical evidence and economic analyses [30][50] - **Future Goals**: The company aims for policy wins by 2025, with ongoing discussions and positive feedback from payers regarding the Sahara RCT [51][55] Conclusion - **Overall Outlook**: Sight Sciences is well-positioned in the interventional glaucoma and dry eye markets, with a strong focus on innovation, clinical evidence, and strategic payer engagement to drive future growth [4][50]

Financial Data and Key Metrics Changes - In Q4 2024, total revenue was $19.1 million, reflecting a 2% increase compared to the same period in the prior year [10][36] - Surgical glaucoma revenue for Q4 2024 was $18.8 million, up 9% year-over-year, driven by a 7% increase in ordering accounts and a 6% increase in account utilization [37][16] - Dry eye revenue for Q4 2024 was $0.3 million, a decrease from $1.6 million in the same period last year, primarily due to fewer SmartLid sales [38][36] - Gross margin for Q4 was 87%, an increase from 85% in the prior year, mainly due to an improved surgical glaucoma product mix [39] - The net loss for Q4 was $11.8 million, or $0.23 per share, compared to a net loss of $10.7 million, or $0.22 per share for Q4 2023 [39] Business Line Data and Key Metrics Changes - Surgical glaucoma revenue grew 9% year-over-year, despite headwinds from new Medicare LCDs [16][37] - The number of customers ordering surgical glaucoma products increased by 3% sequentially and 7% year-over-year [38] - The dry eye segment is focused on achieving reimbursed market access, with a significant decline in revenue due to strategic shifts [36][25] Market Data and Key Metrics Changes - The MIGS market has faced challenges due to new Medicare LCDs, impacting the ability to bill for multiple MIGS procedures [17][19] - Despite short-term declines in MIGS utilization, the company anticipates long-term growth driven by increasing patient demand for glaucoma treatment [19][42] - The company estimates over 13 million U.S. patients are diagnosed with Meibomian gland disease, indicating a significant market opportunity for TearCare [25] Company Strategy and Development Direction - The company aims to build commercial momentum in MIGS and establish equitable reimbursement for TearCare, focusing on customer education and engagement [13][34] - Plans for 2025 include launching the next-generation Omni Edge and continuing to develop the Pseudophakic standalone market [21][45] - The company is committed to addressing the unmet needs in glaucoma and dry eye markets through innovative interventional technologies [11][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow break-even without raising additional equity capital [35] - The company expects 2025 to be transformational, anticipating positive coverage decisions for TearCare [14][41] - Management acknowledged the impact of tariffs on gross margins and operational results, while planning to mitigate these costs through various adjustments [44][45] Other Important Information - The company ended Q4 with $120.4 million in cash and cash equivalents and $40 million in debt [40] - The company has not yet received monetary damages from a patent infringement case against Alcon, with the final ruling pending [41] Q&A Session Summary Question: How is market development on the standalone MIGS market going? - Management noted good momentum in capturing broader adoption of interventional mindset in glaucoma care, with ongoing education efforts [48][51] Question: Can you provide updates on TearCare reimbursement claims? - Management reported increasing volume of claims with some early traction from specific payers, but standardization is still lacking [58][61] Question: What are the trends in surgical glaucoma since the new LCDs? - Management indicated that trends are tracking as expected, with good engagement from customers on where OMNI fits into treatment paradigms [66][70] Question: How is the competitive landscape affecting OMNI volumes? - Management expressed confidence in OMNI's strong market position despite new entrants, emphasizing the importance of clinical evidence and usability [115][117]